Exposing a β-Lactamase “Twist”: the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase
暂无分享,去创建一个
R. Bonomo | H. Schweizer | K. Papp-Wallace | M. L. Winkler | M. Taracila | Drew A. Rholl | S. Becka | Julian A. Gatta
[1] Jordan P Volpato,et al. Combinatorial active‐site variants confer sustained clavulanate resistance in BlaC β‐lactamase from Mycobacterium tuberculosis , 2015, Protein science : a publication of the Protein Society.
[2] Kathryn M Hart,et al. Discovery of multiple hidden allosteric sites by combining Markov state models and experiments , 2015, Proceedings of the National Academy of Sciences.
[3] B. Currie. Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment , 2015, Seminars in Respiratory and Critical Care Medicine.
[4] Paul R. Carey,et al. Following Drug Uptake and Reactions inside Escherichia coli Cells by Raman Microspectroscopy , 2014, Biochemistry.
[5] R. Bonomo,et al. Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. , 2013, Diagnostic microbiology and infectious disease.
[6] R. Bonomo,et al. Insights into β-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants* , 2013, The Journal of Biological Chemistry.
[7] R. Bonomo,et al. Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. , 2013, Journal of medicinal chemistry.
[8] S. Mobashery,et al. Bacterial cell‐wall recycling , 2013, Annals of the New York Academy of Sciences.
[9] H. Schweizer. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. , 2012, Future microbiology.
[10] P. Keim,et al. Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection , 2012, Infection and drug resistance.
[11] R. Bonomo,et al. Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase , 2012, The Journal of Biological Chemistry.
[12] D. Ehmann,et al. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.
[13] Robert A. Bonomo,et al. Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276 , 2012, Antimicrobial Agents and Chemotherapy.
[14] D. Engelthaler,et al. Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia , 2012, PloS one.
[15] H. Schweizer,et al. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei , 2011, Proceedings of the National Academy of Sciences.
[16] R. Bonomo,et al. Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei , 2011, Front. Microbio..
[17] R. Bonomo,et al. Elucidating the role of Trp105 in the KPC‐2 β‐lactamase , 2010, Protein science : a publication of the Protein Society.
[18] R. Bonomo,et al. Inhibitor Resistance in the KPC-2 β-Lactamase, a Preeminent Property of This Class A β-Lactamase , 2009, Antimicrobial Agents and Chemotherapy.
[19] S. Puthucheary,et al. Variations in Ceftazidime and Amoxicillin-Clavulanate Susceptibilities within a Clonal Infection of Burkholderia pseudomallei , 2009, Journal of Clinical Microbiology.
[20] P. Nordmann,et al. Naturally Occurring Class A ß-Lactamases from the Burkholderia cepacia Complex , 2008, Antimicrobial Agents and Chemotherapy.
[21] M. Aschi,et al. Natural D240G Toho-1 mutant conferring resistance to ceftazidime: biochemical characterization of CTX-M-43. , 2008, The Journal of antimicrobial chemotherapy.
[22] A. Cheng,et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] R. Bonomo,et al. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates. , 2006, Biochemistry.
[24] M. Page,et al. The kinetics of non-stoichiometric bursts of-lactam hydrolysis catalysed by class C f-lactamases , 2005 .
[25] Richard A. Moore,et al. Burkholderia pseudomallei Class A β-Lactamase Mutations That Confer Selective Resistance against Ceftazidime or Clavulanic Acid Inhibition , 2003, Antimicrobial Agents and Chemotherapy.
[26] R. Bonomo,et al. Unexpected Advanced Generation Cephalosporinase Activity of the M69F Variant of SHV β-Lactamase* 210 , 2002, The Journal of Biological Chemistry.
[27] V. Wuthiekanun,et al. Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. , 2002, The Journal of antimicrobial chemotherapy.
[28] Brian K Shoichet,et al. The Structural Bases of Antibiotic Resistance in the Clinically Derived Mutant β-Lactamases TEM-30, TEM-32, and TEM-34* , 2002, The Journal of Biological Chemistry.
[29] Yun Zhang,et al. Molecular dynamics at the root of expansion of function in the M69L inhibitor-resistant TEM beta-lactamase from Escherichia coli. , 2002, Journal of the American Chemical Society.
[30] S. Madec,et al. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors. , 2002, FEMS microbiology letters.
[31] P. Woo,et al. Cloning and Expression of Class A β-Lactamase Gene blaABPS in Burkholderia pseudomallei , 2002, Antimicrobial Agents and Chemotherapy.
[32] K. Yuen,et al. Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei. , 2002, Antimicrobial agents and chemotherapy.
[33] M. Samuel,et al. Interventions for treating melioidosis. , 2002, The Cochrane database of systematic reviews.
[34] G. Paul,et al. Catalytic and structural properties of IRT-21 beta-lactamase (TEM-77) from a co-amoxiclav-resistant Proteus mirabilis isolate. , 2001, FEMS microbiology letters.
[35] I. Massova,et al. Effects on Substrate Profile by Mutational Substitutions at Positions 164 and 179 of the Class A TEMpUC19 β-Lactamase from Escherichia coli* , 1999, The Journal of Biological Chemistry.
[36] R. Bonomo,et al. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme. , 1998, The Biochemical journal.
[37] R. Labia,et al. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling. , 1998, Biochimica et biophysica acta.
[38] R. Labia,et al. Clinical inhibitor-resistant mutants of the β-lactamase TEM-1 at amino-acid position 69 , 1998 .
[39] R. Bonomo,et al. Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase. , 1995, Biochimica et Biophysica Acta.
[40] M. Page,et al. The kinetics of non-stoichiometric bursts of beta-lactam hydrolysis catalysed by class C beta-lactamases. , 1993, Biochemical Journal.
[41] J. Samama,et al. Site-directed mutagenesis at the active site of Escherichia coli TEM-1 beta-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis. , 1992, The Journal of biological chemistry.
[42] S. Waley. The kinetics of substrate-induced inactivation. , 1991, The Biochemical journal.
[43] D. Dance,et al. Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase , 1991, Antimicrobial Agents and Chemotherapy.
[44] D. Dance,et al. Pseudomonas pseudomallei Resistance tor-Lactam Antibiotics Due toAlterations intheChromosomally Encoded1-Lactamase , 1991 .
[45] J. Waitz. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .
[46] Pratt Rf,et al. Mechanism of inhibition of the PC1 .beta.-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3'-leaving group , 1985 .
[47] R. Pratt,et al. Mechanism of inhibition of the PC1 beta-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3'-leaving group. , 1985, Biochemistry.
[48] A. Samuni,et al. Acquisition of substrate-specific parameters during the catalytic reaction of penicillinase. , 1976, Proceedings of the National Academy of Sciences of the United States of America.